Recent developments include extension of RhNELL-1 shelf life to 32 months, multiple equity financings including a $9 million private placement and a $5 million public offering with warrants, and implementation of a 1-for-6 reverse stock split.

• Bone Biologics extended the shelf life of its RhNELL-1 protein to 32 months, enhancing study readiness [N1].
• The company priced up to $9 million in a private placement of shares and warrants, supporting capital needs [N2].
• Bone Biologics priced a $5 million public offering with warrants at $4 per share to raise funds for operations [N3].
• Implemented a 1-for-6 reverse stock split effective June 10, 2025, adjusting share structure [N5].
• Reported quarterly earnings with a net loss and ongoing development expenses [N6].
• Announced pricing of a $2 million public offering to support clinical and operational activities [N7].
• Authorized for a 1-for-8 reverse stock split in December 2023 as part of capital structure management [N8].

Bone Biologics has developed a novel, target-specific bone regeneration technology with potential applications across spinal fusion, trauma, and osteoporosis markets, representing multi-billion dollar opportunities. The company has demonstrated progress through preclinical and early clinical milestones, including a pilot clinical study in Australia and successful manufacturing scale-up. The NELL-1/DBM product aims to offer improved safety and efficacy compared to existing bone growth agents, potentially addressing unmet clinical needs. Exclusive licensing agreements and a growing intellectual property portfolio support competitive positioning. Recent financings provide capital to advance clinical development and regulatory submissions.

Bone Biologics operates in a highly competitive and regulated environment with significant risks including the need for successful clinical trial outcomes and FDA pre-market approval. The company has a limited operating history, ongoing net losses, and depends on raising additional capital to fund operations. There is risk of product development delays, regulatory setbacks, and potential challenges in market acceptance. The company faces competition from large orthopedic and biotech firms with greater resources. Additionally, Bone Biologics is subject to Nasdaq listing risks due to market value requirements, which could impact liquidity and capital raising ability.

Bone Biologics' moat is primarily based on its exclusive worldwide license to the NELL-1 technology platform from UCLA TDG, which includes multiple patents covering manufacture, composition, and clinical applications. The proprietary nature of the recombinant human protein NELL-1, combined with its demonstrated target-specific bone regeneration properties and safety profile, provides a technological barrier to entry. The company's clinical-stage status and ongoing regulatory approvals further create hurdles for competitors. However, the company faces competition from large, well-resourced orthopedic and biotechnology firms with established market presence and product portfolios.

• Regulatory Approval Risk: Bone Biologics must obtain FDA pre-market approval for its NELL-1/DBM product, which requires successful completion of clinical trials and regulatory review. Delays or failures in this process could impede commercialization.
• Capital and Liquidity Risk: The company has incurred net losses and depends on raising additional equity or debt financing to fund operations and clinical development. Insufficient capital could force scaling back or discontinuation of programs.
• Market Listing Risk: Bone Biologics is not currently in compliance with Nasdaq's market value listing standards, which could lead to delisting, adversely affecting stock liquidity and capital raising.
• Competition Risk: The company faces competition from large, established orthopedic and biotechnology companies with greater resources and market presence, which could limit market penetration.
• Clinical Trial Risk: Clinical trials may encounter delays, adverse events, or fail to demonstrate safety and efficacy, impacting regulatory approval and market acceptance.

• Bone Biologics Corp is a clinical-stage medical device company focused on bone regeneration in spinal fusion using recombinant human protein NELL-1 combined with demineralized bone matrix (DBM).
• The NELL-1/DBM product is an osteopromotive recombinant protein providing target-specific control over bone regeneration.
• The company holds exclusive worldwide license rights to NELL-1 technology from UCLA Technology Development Group (UCLA TDG).
• NELL-1/DBM is classified by the FDA as a device/drug combination product requiring pre-market approval (PMA) before commercialization in the US.
• Bone Biologics was founded in 2004 by university professors and surgeons and has validated its platform in sheep and non-human primate models.
• The lead product candidate, NB1, is a NELL-1 protein combined with FDA-cleared DBM putty from MTF Biologics, intended for lumbar spinal fusion.
• NB1 is being evaluated in a multicenter, prospective, randomized pilot clinical study in Australia for safety and effectiveness in spinal degenerative disc disease patients.
• The pilot study enrolls up to 30 adult subjects undergoing transforaminal lumbar interbody fusion (TLIF) and measures fusion success and pain/function improvement at 12 months.
• The company has completed key milestones including manufacturing pilot runs, large animal studies, pivotal animal studies, and initiation of first-in-man clinical trials.
• NELL-1 technology has potential applications beyond spinal fusion including non-union trauma cases and osteoporosis, addressing multi-billion dollar global markets.
• Bone Biologics has an intellectual property portfolio including exclusive licenses to multiple UCLA TDG patents covering NELL-1 manufacture, composition, and use.
• The company has incurred net losses since inception and is dependent on raising additional capital to fund operations and clinical development.
• Financial snapshot as of 2026-06-30 shows cash and equivalents of $6.19 million, current assets of $4.44 million, current liabilities of $0.51 million, with a current ratio of 8.67 and cash ratio of 12.09.
• For the quarter ended 2026-06-30, Bone Biologics reported a net loss of $773,702 and basic and diluted EPS of -$0.43.
• Bone Biologics has conducted multiple equity financings including a $5 million public offering with warrants in 2025 and a $9 million private placement in 2026.
• The company implemented a 1-for-6 reverse stock split effective June 10, 2025, and was previously authorized for a 1-for-8 reverse stock split in 2023.
• Bone Biologics faces competition from large orthopedic and biotechnology companies such as Medtronic, Stryker, Globus Medical, and DePuy-Synthes.
• The company is subject to extensive FDA regulation and must complete rigorous preclinical and clinical testing before product commercialization.
• Bone Biologics has obligations to UCLA TDG including milestone payments upon clinical study enrollment, pre-market approval, and commercial sales, as well as royalties on net sales.
• The company faces risks including potential delisting from Nasdaq due to market value requirements, liquidity constraints, and the need for additional capital.
• Bone Biologics' NELL-1/DBM product aims to provide a safer alternative to existing bone growth agents with fewer inflammatory side effects.
• The company’s clinical trial design and regulatory strategy have been reviewed and agreed upon by the FDA’s Division of Orthopedic Devices.
• Bone Biologics’ research and development expenses were approximately $1.06 million in 2025 and $2.13 million in 2024.
• The company’s lead product candidate NB1 is intended to be used with existing spinal fusion hardware without requiring changes to surgical protocols.
• Bone Biologics’ NELL-1 protein selectively targets cells involved in bone formation, potentially improving bone regeneration quality and safety.
• Recent news includes extension of RhNELL-1 shelf life to 32 months, strengthening study readiness, and multiple financings to support development and operations.